Determination of tranexamic acid (AMCA) and fibrin/fibrinogen degradation products in cerebrospinal fluid after aneurysmal subarachnoid haemorrhage.
Six patients with recently ruptured intracranial aneurysms were treated preoperatively with tranexamic acid (AMCA). Two patients received 6 g daily in i.v. infusion, two had 6 g daily by i.v. injection, and two patients were given AMCA 9 g daily by mouth during the first week after bleeding. Serial assays of AMCA and fibrin/fibrinogen degradation products (FDP) in cerebrospinal fluid (CSF) were performed during 6--13 days after the initial subarachnoid haemorrhage (SAH). Judged from the decline in CSF-FDP, an assumed therapeutic level of greater than or equal to 1 mg/l of AMCA in CSF was reached within 24--36 hours after the first dose when the drug was administered intravenously and within 48 hours when the drug was given orally.
D000328:Adult; D001711:Biotransformation; D003509:Cyclohexanecarboxylic Acids / Q000134:cerebrospinal fluid*; D004334:Drug Administration Schedule; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000134:cerebrospinal fluid*; D006801:Humans; D002532:Intracranial Aneurysm / Q000134:cerebrospinal fluid* / Q000150:complications; D008875:Middle Aged; D013345:Subarachnoid Hemorrhage / Q000134:cerebrospinal fluid* / Q000188:drug therapy; D014148:Tranexamic Acid / Q000008:administration & dosage / Q000134:cerebrospinal fluid*
D003509:Cyclohexanecarboxylic Acids; D005338:Fibrin Fibrinogen Degradation Products; D014148:Tranexamic Acid